Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 2/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749303 | 0.83 | GPR119 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2595915 | 0.76 | PNMT (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL14575755 | 0.76 | GPR119 (0.48) | GPR119USP30 | |
| SCHEMBL14749306 | 0.75 | GPR119 (0.35) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL9936687 | 0.74 | GPR119 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2595423 | 0.73 | GPR119 (0.66) | CHRM2GPR119 | |
| SCHEMBL9936136 | 0.72 | GPR119 (0.56) | CHRM2GPR119 | |
| SCHEMBL9936121 | 0.72 | GPR119 (0.47) | GPR119USP30 | |
| SCHEMBL2595425 | 0.69 | GPR119 (0.66) | GPR119 | |
| SCHEMBL14575435 | 0.68 | GPR119 (0.45) | GPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729084-B2 | Benzofuranyl analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130059858-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059858-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | GPR119, GPR180, GPR139 | CHRM2 143/4885CHRM4 289/4885CHRM5 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.